Literature DB >> 21035400

Energy metabolism in amyotrophic lateral sclerosis.

Luc Dupuis1, Pierre-François Pradat, Albert C Ludolph, Jean-Philippe Loeffler.   

Abstract

Amyotrophic lateral sclerosis (ALS) is characterised by the progressive degeneration of upper and lower motor neurons. Besides motor neuron degeneration, ALS is associated with several defects in energy metabolism, including weight loss, hypermetabolism, and hyperlipidaemia. Most of these abnormalities correlate with duration of survival, and available clinical evidence supports a negative contribution of defective energy metabolism to the overall pathogenic process. Findings from animal models of ALS support this view and provide insights into the underlying mechanisms. Altogether, these results have clinical consequences for the management of defective energy metabolism in patients with ALS and pave the way for future therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21035400     DOI: 10.1016/S1474-4422(10)70224-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  174 in total

Review 1.  Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis.

Authors:  Peter W French; Russell Ludowyke; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2018-12-05       Impact factor: 3.911

Review 2.  Neural Control of Energy Expenditure.

Authors:  Heike Münzberg; Emily Qualls-Creekmore; Hans-Rudolf Berthoud; Christopher D Morrison; Sangho Yu
Journal:  Handb Exp Pharmacol       Date:  2016

3.  Motor neuron disease: Are diabetes and amyotrophic lateral sclerosis related?

Authors:  Giancarlo Logroscino
Journal:  Nat Rev Neurol       Date:  2015-08-18       Impact factor: 42.937

4.  Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: A population based study.

Authors:  Marianthi-Anna Kioumourtzoglou; Ryan M Seals; Ole Gredal; Murray A Mittleman; Johnni Hansen; Marc G Weisskopf
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-07-20       Impact factor: 4.092

5.  Early and progressive impairment of spinal blood flow-glucose metabolism coupling in motor neuron degeneration of ALS model mice.

Authors:  Kazunori Miyazaki; Kazuto Masamoto; Nobutoshi Morimoto; Tomoko Kurata; Takahumi Mimoto; Takayuki Obata; Iwao Kanno; Koji Abe
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-09       Impact factor: 6.200

Review 6.  Acetyltransferases (HATs) as targets for neurological therapeutics.

Authors:  Anne Schneider; Snehajyoti Chatterjee; Olivier Bousiges; B Ruthrotha Selvi; Amrutha Swaminathan; Raphaelle Cassel; Frédéric Blanc; Tapas K Kundu; Anne-Laurence Boutillier
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 7.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Anne-Marie Wills; Jane Hubbard; Eric A Macklin; Jonathan Glass; Rup Tandan; Ericka P Simpson; Benjamin Brooks; Deborah Gelinas; Hiroshi Mitsumoto; Tahseen Mozaffar; Gregory P Hanes; Shafeeq S Ladha; Terry Heiman-Patterson; Jonathan Katz; Jau-Shin Lou; Katy Mahoney; Daniela Grasso; Robert Lawson; Hong Yu; Merit Cudkowicz
Journal:  Lancet       Date:  2014-02-28       Impact factor: 79.321

9.  Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-19       Impact factor: 6.200

10.  Acyl coenzyme A thioesterase 7 regulates neuronal fatty acid metabolism to prevent neurotoxicity.

Authors:  Jessica M Ellis; G William Wong; Michael J Wolfgang
Journal:  Mol Cell Biol       Date:  2013-03-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.